Zogenix out of San Diego, California has received FDA approval for the single use DosePro™ device. The needle free system delivers sumatriptan, a drug often prescribed for migraines, through the skin for a faster effect than a tablet. Sumatriptan in a tablet form is best known under its IMITREX® brand name.
Sumatriptan DosePro (formerly known as Intraject® sumatriptan) utilizes Zogenix’s proprietary DosePro needle-free drug delivery system to subcutaneously administer sumatriptan for the treatment of migraine and cluster headache. Sumatriptan DosePro is a fast-acting therapy that patients can self administer in three easy steps. Based on Zogenix’s clinical bioequivalence studies, the company has concluded that sumatriptan DosePro is bioequivalent to injectable sumatriptan (IMITREX STATdose System®) when administered in the thigh or abdomen. Given the unique attributes of sumatriptan DosePro, Zogenix believes it has the potential to be used as a replacement for needle-based injectable forms of sumatriptan, as well as oral and nasal spray triptans.